Ling Gui-Chen, Zhang Shan, Guo Ying-Ao, Yang Shuo, Li Zhi-Ling, Zhang Jian-Yong, Xie Jing-Jing
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, China.
Lupus. 2025 Feb;34(2):187-192. doi: 10.1177/09612033241309838. Epub 2024 Dec 20.
Lupus cystitis, a severe complication of systemic lupus erythematosus (SLE), presents considerable treatment challenges.
This case report describes the use of telitacicept in treating severe SLE with lupus cystitis.
A single patient with lupus cystitis.
A patient with symptoms including frequent urination, urgency, and acute urinary retention.
Initial treatments included corticosteroid pulse therapy, immunoglobulin, and cyclophosphamide, which improved laboratory indicators but failed to alleviate symptoms of urinary retention. The patient was then treated with telitacicept.
Significant alleviation of urinary retention was observed shortly after incorporating telitacicept into the treatment regimen. The patient's condition remained stable with no relapse during the subsequent 10 months of follow-up.
This case highlights the therapeutic potential of telitacicept for SLE patients who are unresponsive to conventional therapies, particularly those with severe manifestations such as lupus cystitis.
狼疮性膀胱炎是系统性红斑狼疮（SLE）的一种严重并发症，带来了相当大的治疗挑战。
本病例报告描述了泰它西普在治疗伴有狼疮性膀胱炎的重症SLE中的应用。
一名患有狼疮性膀胱炎的患者。
一名有尿频、尿急和急性尿潴留等症状的患者。
初始治疗包括糖皮质激素冲击疗法、免疫球蛋白和环磷酰胺，这些改善了实验室指标，但未能缓解尿潴留症状。然后该患者接受了泰它西普治疗。
在将泰它西普纳入治疗方案后不久，观察到尿潴留明显缓解。在随后10个月的随访中，患者病情保持稳定，未复发。
本病例突出了泰它西普对常规治疗无反应的SLE患者，特别是那些有狼疮性膀胱炎等严重表现患者的治疗潜力。
